These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34936710)

  • 1. Human mesenchymal stem cells.
    Chen X; Huang J; Wu J; Hao J; Fu B; Wang Y; Zhou B; Na T; Wei J; Zhang Y; Li Q; Hu S; Zhou J; Yu J; Wu Z; Zhu H; Cao J; Wang L; Peng Y; Liang L; Ma A; Zhang Y; Zhao T; Xiang AP
    Cell Prolif; 2022 Apr; 55(4):e13141. PubMed ID: 34936710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human neural stem cells.
    Wang YK; Yu J; Zhang TT; Ma AJ; Hao J; Chen YJ; Liu CM; Liu Y; Wang CL; Zhai PJ; Xiang AP; Li TQ; Tang TS; Chen H; Bao XJ; Wang YL; He WY; Fan J; Teng ZQ; Wang L; Zhou JX; Fu BQ; Fu YV; Feng L; Cao JN; Liang LM; Wang L; Zhou Q; Zhang Y; Hu BY; Zhao TB
    Cell Prolif; 2024 Apr; 57(4):e13564. PubMed ID: 37853840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirements for human natural killer cells.
    Niu S; Xia C; Huang D; Wang L; Hu H; Yu S; Wu N; Dong Z; Zhou J; Wu J; Yu J; Zhang Y; Wang C; Fu B; Cao J; Liang L; Xu L; Chen L; Zhou Q; Ma A; Zhao T; Hao J; Wang J
    Cell Prolif; 2024 May; 57(5):e13588. PubMed ID: 38124457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirements for human embryonic stem cells.
    Hao J; Cao J; Wang L; Ma A; Chen S; Ding J; Wang L; Fu B; Zhang Y; Pei X; Xiang P; Li Q; Zhang Y; Zhou J; Hu S; Yu J; Wei J; Zhu H; Stacey G; Zhao T; Zhou Q
    Cell Prolif; 2020 Dec; 53(12):e12925. PubMed ID: 33073898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirments for primary human hepatocyte.
    Peng Z; Wu J; Hu S; Ma A; Wang L; Cao N; Zhang Y; Li Q; Yu J; Meng S; Na T; Shi X; Li M; Liu H; Qian L; Tian E; Lin F; Cao J; Peng Y; Zhu H; Liang L; Hao J; Zhao T; Cheng X; Pan G
    Cell Prolif; 2022 Apr; 55(4):e13147. PubMed ID: 34936148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human retinal pigment epithelial cells.
    Wang L; Cao J; Peng Y; Fu B; Jin Z; Hu Y; Wu W; Xiang AP; Hu S; Yu J; Zhang Y; Wei J; Zhang Y; Li Q; Zhou J; Zhai P; Zhu H; Liang L; Ma A; Stacey G; Zhao T; Hao J
    Cell Prolif; 2022 Apr; 55(4):e13153. PubMed ID: 34773310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirements for human cardiomyocytes.
    Yu M; Lei W; Cao J; Wang L; Ma A; Zhao ZA; Yang HT; Shen Z; Lan F; Cao F; Liang P; Pei X; Xiang AP; Yu J; Zhang Y; Zhang Y; Li Q; Zhou J; Wei J; Peng Y; Zhu H; Liang L; Cao N; Fu B; Hao J; Zhao T; Hu S
    Cell Prolif; 2022 Apr; 55(4):e13150. PubMed ID: 34708452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirements for human-induced pluripotent stem cells.
    Zhang Y; Wei J; Cao J; Zhang K; Peng Y; Deng H; Kang J; Pan G; Zhang Y; Fu B; Hu S; Na J; Liu Y; Wang L; Liang L; Zhu H; Zhang Y; Jin ZB; Hao J; Ma A; Zhao T; Yu J
    Cell Prolif; 2022 Apr; 55(4):e13182. PubMed ID: 35083805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human midbrain dopaminergic progenitors.
    Wang YK; Feng L; Ma AJ; Hao J; Zhang Y; Chen YJ; Chen ZG; Yu JY; Liu Y; Liu CM; Zhang Y; Wang CL; Teng ZQ; Zhou JX; Li TQ; Wang L; Fu BQ; Fu YV; Zhu LJ; Liang LM; Cao JN; Wang L; Zhou Q; Xiang AP; Hu BY; Zhao TB
    Cell Prolif; 2024 Apr; 57(4):e13563. PubMed ID: 37881164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirements for human haematopoietic stem/progenitor cells.
    Nan X; Zhang B; Hao J; Yue W; Fu B; Qu M; Zhang Y; Wang H; Fang F; Wei J; Li Q; Hu S; Yu J; Gao Y; Liu Q; Cao J; Wang L; Peng Y; Zhu H; Liang L; Ma A; Zhou J; Zhao T; Pei X
    Cell Prolif; 2022 Apr; 55(4):e13152. PubMed ID: 34936155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General requirements for stem cells.
    Hao J; Ma A; Wang L; Cao J; Chen S; Wang L; Fu B; Zhou J; Pei X; Zhang Y; Xiang P; Hu S; Li Q; Zhang Y; Xia Y; Zhu H; Stacey G; Zhou Q; Zhao T
    Cell Prolif; 2020 Dec; 53(12):e12926. PubMed ID: 33146418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard: Human intestinal organoids.
    Wang Y; Lin H; Zhao L; Hong F; Hao J; Zhang Z; Sheng W; Song L; Deng CX; Zhao B; Cao J; Wang L; Wang L; Liang L; Chen WK; Yu C; Sun Z; Yang Y; Wang C; Zhang Y; Li Q; Li K; Ma A; Zhao T; Hua G; Chen YG
    Cell Regen; 2023 Jun; 12(1):23. PubMed ID: 37314549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General requirements for the production of extracellular vesicles derived from human stem cells.
    Wang L; Liu S; Li K; Ma A; Hu C; Wang C; Cao N; Zhao Y; Fu R; Jia W; Xiang P; Liu H; Qi Z; Zhu N; Liang L; Wang L; Cao J; Zhai P; Zhou J; Wei J; Na T; Wu J; He Z; Zhou G; Yu W; Wu J; Zeng W; Zhang Y; Zhu L; Fu B; Zhang J; Yang S; Dai C; Cui H; Jing J; Yan H; He X; Lu Y; Tong C; Zhao T; Hao J; Liu X; Jin Y; Wang Y
    Cell Prolif; 2024 Mar; 57(3):e13554. PubMed ID: 37767639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard: Human intestinal cancer organoids.
    Lin H; Wang Y; Cheng C; Qian Y; Hao J; Zhang Z; Sheng W; Song L; Deng CX; Zhao B; Cao J; Wang L; Wang L; Liang L; Chen WK; Yu C; Sun Z; Yang Y; Wang C; Zhang Y; Li Q; Li K; Ma A; Zhao T; Chen YG; Hua G
    Cell Regen; 2023 Jun; 12(1):24. PubMed ID: 37378693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy.
    Li J; Wu Z; Zhao L; Liu Y; Su Y; Gong X; Liu F; Zhang L
    Stem Cell Res Ther; 2023 Dec; 14(1):381. PubMed ID: 38124129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concise Review: Mesenchymal Stem Cells: From Roots to Boost.
    Andrzejewska A; Lukomska B; Janowski M
    Stem Cells; 2019 Jul; 37(7):855-864. PubMed ID: 30977255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review.
    Samadi P; Saki S; Manoochehri H; Sheykhhasan M
    Curr Stem Cell Res Ther; 2021; 16(3):323-353. PubMed ID: 32928093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies.
    Dunn CM; Kameishi S; Grainger DW; Okano T
    Acta Biomater; 2021 Oct; 133():114-125. PubMed ID: 33857693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
    Markov A; Thangavelu L; Aravindhan S; Zekiy AO; Jarahian M; Chartrand MS; Pathak Y; Marofi F; Shamlou S; Hassanzadeh A
    Stem Cell Res Ther; 2021 Mar; 12(1):192. PubMed ID: 33736695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.
    Wu X; Jiang J; Gu Z; Zhang J; Chen Y; Liu X
    Stem Cell Res Ther; 2020 Aug; 11(1):345. PubMed ID: 32771052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.